Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry

Stock Information for VolitionRX Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About VolitionRX Limited

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats
VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update
VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption
VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.